Atrial fibrillation (AF) and coronary artery disease (CAD) sometimes coexist in clinical practice, and the prevalence of CAD in AF patients and AF in percutaneous coronary artery intervention (PCI) patients has been reported to be around 8%--15% in Japan. Those patients are problematic because bleeding and subsequent complications are substantially increased by a combination antithrombotic therapy with anticoagulants and antiplatelet drugs, that is, an oral anticoagulant plus a P2Y12 inhibitor (double therapy) and triple therapy (an oral anticoagulant plus a dual antiplatelet therapy \[DAPT\]). That antithrombotic therapy has clinically been up to the physicians' discretion based on careful consideration to balance the ischemic vs. bleeding risks.

Clinical interest in managing antithrombotic therapy in AF patients undergoing PCI has provided several randomized controlled trials (RCTs). First, the WOEST trial[1](#joa312317-bib-0001){ref-type="ref"} (n = 573) tested the clinical benefit of a dual therapy with a vitamin K antagonist (VKA) plus clopidogrel as a counterpart to the triple therapy of a VKA plus a DAPT. Dual therapy reduced the incidence of major bleeding more than triple therapy, and the incidence of composite cardiovascular events was lower with dual therapy. Furthermore, the PIONEER PCI trial[2](#joa312317-bib-0002){ref-type="ref"} compared the efficacy and safety between dual therapy with rivaroxaban 15 mg plus a P2Y12 inhibitor (n = 709) and triple therapy with a VKA plus DAPT adjusted for 1, 6, or 12 months (n = 706). Similar to the WOEST trial, dual therapy had a lower bleeding risk, but the efficacy endpoint was similar between the dual and triple therapies. A similar tendency was observed in the RE‐DUAL PCI trial[3](#joa312317-bib-0003){ref-type="ref"} (n = 2725) to compare a dual therapy with dabigatran over 12 months and a P2Y12 inhibitor and VKA‐based triple therapy for 1 to 3 months.

Those trials lead to a significant trend in the Recent European and American guidelines for PCI patients with AF. The 2017 focused update ESC/EACTS guidelines recommend triple therapy for 6 months in cases with a high thromboembolic risk, and if a high bleeding risk, triple therapy for 1 month for relatively low risk patients but a DOAC plus clopidogrel are initially recommended after PCI in significantly high risk patients. According to the AHA expert consensus (A North American Perspective 2018), a DOAC plus DAPT plus DAPT should be terminated 1 month after PCI. The 2018 European Heart Rhythm Association (EHRA) recommends a triple therapy DOAC plus DAPT on admission, and thereafter, a DOAC plus clopidogrel for an elective PCI using new generation drug eluting stents (DESs). In acute coronary syndrome (ACS) patients, a triple therapy for 3 months, and thereafter, a DOAC plus clopidogrel are recommended. The Japanese guidelines for stable CAD and ACS patients published in 2018, state that in ACS patients with AF or AF patients undergoing an elective PCI, a triple therapy only on admission (less than 1 month) and subsequent dual therapy is typically recommended.

The Western and Japanese guidelines were published before the AUGUSTUS and ENTRUST trials. In the AUGUSTUS trial[4](#joa312317-bib-0004){ref-type="ref"} published in 2019, 4614 AF patients that underwent a PCI with a P2Y12 inhibitor were randomly assigned to receive apixaban or a VKA and aspirin or a matching placebo for 6 months. The ENTRUST trial[5](#joa312317-bib-0005){ref-type="ref"} was also published in 2019, and 1506 AF patients who underwent PCI for stable CAD or ACS were randomly assigned to either edoxaban plus a P2Y12 inhibitor for 12 months or a VKA plus DAPT (for 1‐12 months). Those two trials also showed consistent bleeding risk reduction results and an equivalent ischemic risk of dual therapy as triple therapy.

The present issue by Pradyumna et al shows a meta‐analysis of all RCTs for four DOACs including dabigatran, rivaroxaban, apixaban, and edoxaban in AF patients that underwent PCI. In the total 6733 patients included in their meta‐analysis, most had CHA2DS2‐VASc scores \>3. In four RCTs, compared to VKA‐based triple therapies, DOAC‐based dual therapies had significantly lower International Society of Thrombosis and Hemostasis major bleeding/clinically relevant nonmajor bleeding (relative risk \[RR\] 0.65, 95% confidence interval \[CI\] 0.48‐0.88. *P* \< .00001). There were no significant differences in the efficacy outcomes including myocardial infarctions (RR 1.12, 95% CI 0.86‐1.46, *P* = .39), stent thromboses (RR 1.41, 95% CI 0.88‐2.27, *P* = .15), ischemic strokes (RR 0.84, 95% CI 0.52‐1.34, *P* = .46), all‐cause mortality (RR 1.10, 95% CI 0.86‐1.41, *P* = .43), and MACE (RR 1.26, 95% CI 0.85‐1.86, *P* = .25). Their findings corroborate the recent RCTs, and there is strong evidence that compared to triple therapies with VKAs, dual therapies with DOACs reduce the bleeding risk and have a similar efficacy in AF patients undergoing PCI. It is important to note that in the patients included in this meta‐analysis, the prevalence of ACS ranged from 30% to 52%, and the time to randomization was within 2 weeks. Their data supports that aspirin can be dropped in the relatively early phase (within less than 2 weeks) after PCI using DESs, and a dual therapy with any type of DOAC and a P2Y12 inhibitor can be used not only in elective PCI patients, but also ACS patients. The mean age was between 68‐70 years, and over 90% were white, and thus, there is always a question as to what extent those RCT results can be clinically applied in Japan because only in the RE‐DUAL PCI trial, were a small number of Japanese patients (n = 111) enroled. In clinical practice, Japanese AF patients tend to be elderly and have a lower body weight and multiple co‐morbidities treated by multiple medications. Furthermore, Asians including Japanese have been known to be at higher risk of bleeding than Westerners. An adjusted‐dose (3.75 mg) prasugrel, one of the P2Y12 inhibitors, is used for Japanese patients, and it was not included in those RCTs. Despite those unresolved issues, this meta‐analysis and four clinical trials on DOACs used in PCI patients will advance the future guidelines regarding the efficacy of a dual therapy with different types of DOACs in AF patients with CAD and may give cardiologists confidence in dual therapies during the early phase after PCI.
